Gilde Healthcare participates in $93 million equity round for cardiovascular company CVRx - Gilde Healthcare

Gilde Healthcare participates in $93 million equity round for cardiovascular company CVRx

10 augustus 2016

Equity Offering to Support Heart Failure Trial and European Commercial Expansion

Minneapolis – CVRx, Inc., a private medical device company, has announced an equity financing totaling $93 million. Gilde Healthcare participated in the financing alongside existing investors, Johnson & Johnson Innovation—JJDC, and New Enterprise Associates. CVRx is the first investment from the newly raised Gilde Healthcare IV fund which closed a few weeks ago at its hard cap of EUR 250 million.

CVRx has developed the second-generation BAROSTIM NEO, a minimally-invasive implantable neurostimulator, and the only device CE Marked for the separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure in the United States. CVRx plans to use the proceeds of this financing for the primary purposes of completing the Baroreflex Activation Therapy for Heart Failure Pivotal Clinical Trial (BeAT-HF) and expanding its global commercial activities.

In the United States and Europe, heart failure is estimated to affect 15 million adults, and is associated with a four-fold increased risk of death and a six to nine times increased risk of sudden cardiac death. The direct and indirect costs of heart failure are estimated to be $32 billion in the United States alone. Geoff Pardo from Gilde, who will join the CVRx Board of Directors, commented, “We are extremely excited to join the CVRx team. Heart failure not only represents one of the biggest unmet clinical needs, but the costs associated with treatment represent a significant burden on health systems globally. CVRx has the potential to dramatically improve clinical outcomes and reduce the cost of care for this patient population.”

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde is currently investing out of GHC IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at gildehealthcare.com.

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling...
9 juli 2025

Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neuro-imaging

Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy (fNIRS). Door deze dubbele transactie...
8 juli 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
11 juni 2025